Verition Fund Management
COGT icon

Verition Fund Management’s Cogent Biosciences COGT Stock Holding History

Verition Fund Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59,456
Closed -$2.11M – 2513
2025
Q4 		$2.11M Buy
59,456
+42,342
+247% +$1.19M 0.01% 1556
2025
Q3 		$246K Sell
17,114
-81,475
-83% -$965K ﹤0.01% 3391
2025
Q2 		$708K Buy
98,589
+56,760
+136% +$315K ﹤0.01% 2718
2025
Q1 		$251K Sell
41,829
-21,695
-34% -$170K ﹤0.01% 2945
2024
Q4 		$495K Buy
63,524
+32,296
+103% +$322K ﹤0.01% 2495
2024
Q3 		$337K Buy
31,228
+2,176
+7% +$21.2K ﹤0.01% 2565
2024
Q2 		$245K Buy
29,052
+18,204
+168% +$138K ﹤0.01% 2474
2024
Q1 		$72.9K Buy
+10,848
New +$67.1K ﹤0.01% 2612
2023
Q2 		– Sell
-11,920
Closed -$129K – 2248
2023
Q1 		$129K Buy
+11,920
New +$152K ﹤0.01% 1878

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Verition Fund Management's COGT Position: Q1 2026 in Review

Verition Fund Management sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 59,456 shares — an estimated $2.11M sold.

Verition Fund Management first reported a position in COGT in Q1 2023 and held it in 9 quarters. The position peaked at $2.11M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Verition Fund Management reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 59,456 Cogent Biosciences shares in Q1 2026, an estimated $2.11M.
  • Verition Fund Management first reported a position in Cogent Biosciences in Q1 2023 and held it in 9 quarters.
  • Verition Fund Management's Cogent Biosciences position peaked at $2.11M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.